Plain-English translation of NCT06498752 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a blood test that detects leftover cancer cells — called minimal residual disease (MRD) testing — can help doctors decide who truly needs additional immune therapy after radiation treatment for esophageal cancer. Right now, doctors give extra treatment to almost everyone, even patients who may not need it. This study aims to use the blood test to identify only those patients who would actually benefit from the medication, potentially sparing others from unnecessary side effects.
Esophageal cancer is difficult to treat, and even after radiation and chemotherapy, survival rates are still quite low. Doctors want to add immune-boosting treatment to help more patients, but they don't have a reliable way to know who truly needs it—so many patients may be getting treatment they don't need. This trial uses an advanced blood test to solve that problem, so doctors can give the right treatment to the right patients.
You likely qualify if…
You likely don't qualify if…
After you finish your radiation and chemotherapy, you'll have a blood test to check for leftover cancer cells. If the test is negative, you'll come back every 3 months for 2 years for CT scans, throat X-rays, and repeat blood tests to make sure you stay cancer-free. If the test is positive, you'll receive additional immune therapy (PD-1 monoclonal antibody) along with the same monitoring schedule. The trial lasts up to 2 years from the end of your radiation treatment.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborators
Peking University Cancer Hospital & Institute, Hebei Medical University Fourth Hospital
Enrollment target
~102 participants
Started
July 2024
Primary completion
June 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2024.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.